edoc

Research and development of antischistosomal drugs in the People's Republic of China a 60-year review

Xiao, S. H. and Keiser, J. and Chen, M. G. and Tanner, M. and Utzinger, J.. (2010) Research and development of antischistosomal drugs in the People's Republic of China a 60-year review. Advances in parasitology, Vol. 73. pp. 231-295.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A5843009

Downloads: Statistics Overview

Abstract

A comprehensive 60-year review of antischistosomal drug discovery and development research in the People's Republic of China (P.R. China) is presented. In the 1950s, three antimonials were developed, which, compared to potassium antimony tartrate-the treatment of choice against schistosomiasis at the time-showed equal efficacy but lower toxicity when administered orally or intramuscularly. Activity of furapromidum against Schistosoma japonicum was reported in the early 1960s, and this drug became the first non-antimonial used in clinical treatment of schistosomiasis japonica. Subsequently, two additional nitrofuran derivatives (furadiamine and fuvinazole) were investigated in the laboratory and clinically. In the late 1960s, niridazole and amoscanate were developed by western scientists, which encouraged Chinese researchers to synthesise and further modify the chemical structures of these compounds. However, the modified compounds were less efficacious but similarly toxic, which impeded their further development. The advent of the safe, highly efficacious broad-spectrum antischistosomal drug praziquantel, in the mid-1970s, eventually resulted in a change of the global schistosomiasis control strategy from a multi-pronged transmission control approach to drug-based morbidity control. Numerous studies were carried out in P.R. China to further the understanding of efficacy, mechanism of action and safety of praziquantel against S. japonicum. Efforts have also been made to develop antischistosomal drugs from Chinese traditional medicine, and research with cucurbitin (an amino acid isolated from pumpkin seeds), among other products, showed interesting in vitro and in vivo activities against S. japonicum. In the 1990s, the artemisinins-originally reserved for malaria treatment-were developed as 'chemoprophylactic' agents against S. japonicum, which in turn led to a series of new developments of artemisinins and related compounds as broad-spectrum antischistosomal and anthelminthic therapies.
Faculties and Departments:09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH) > Department of Medical Parasitology and Infection Biology > Helminth Drug Development (Keiser)
03 Faculty of Medicine > Departement Public Health > Sozial- und Präventivmedizin > Malaria Vaccines (Tanner)
09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH) > Department of Epidemiology and Public Health (EPH) > Health Interventions > Malaria Vaccines (Tanner)
09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH) > Department of Epidemiology and Public Health (EPH) > Eco System Health Sciences > Health Impact Assessment (Utzinger)
UniBasel Contributors:Tanner, Marcel and Keiser, Jennifer and Utzinger, Jürg
Item Type:Article, refereed
Article Subtype:Research Article
Bibsysno:Link to catalogue
Publisher:Elsevier
ISSN:0065-308X
Note:Also published in: Important helminth infections in southeast Asia : diversity and potential for control and elimination. - Amsterdam : Elsevier. - Part B, S. 231-295 -- Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:09 Jan 2015 09:25
Deposited On:08 Jun 2012 06:48

Repository Staff Only: item control page